{
    "id": "dbpedia_8093_1",
    "rank": 7,
    "data": {
        "url": "https://www.linkedin.com/posts/olphaglobal_olpha-withinreach-activity-7209182164259622912-yJ5x",
        "read_more_link": "",
        "language": "en",
        "title": "Olpha on LinkedIn: #olpha #withinreach",
        "top_image": "https://media.licdn.com/dms/image/v2/D5605AQGlcxsNwzj0LQ/videocover-high/videocover-high/0/1718802962929?e=2147483647&v=beta&t=B-UlVzlrMjk3XZRXEDGcYthlArU1VjmGtGVJbabaMJA",
        "meta_img": "https://media.licdn.com/dms/image/v2/D5605AQGlcxsNwzj0LQ/videocover-high/videocover-high/0/1718802962929?e=2147483647&v=beta&t=B-UlVzlrMjk3XZRXEDGcYthlArU1VjmGtGVJbabaMJA",
        "images": [
            "https://media.licdn.com/dms/image/v2/D4D3DAQElY1ES61T9Ig/image-scale_191_1128/image-scale_191_1128/0/1718789335319/olphaglobal_cover?e=2147483647&v=beta&t=c-zzlYQZmZmsKbXEYaBsgkjBkzk55sQ-1CLsHxwIpdM"
        ],
        "movies": [
            "https://dms.licdn.com/playlist/vid/v2/D5605AQGlcxsNwzj0LQ/mp4-640p-30fp-crf28/mp4-640p-30fp-crf28/0/1718802965530?e=2147483647&v=beta&t=XpvLCb_0JKzkXlx9W8TSGq-b29ob7cWhw85gkUJxgfY"
        ],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Olpha"
        ],
        "publish_date": "2024-06-19T13:16:08.072000+00:00",
        "summary": "",
        "meta_description": "Starting today, Olainfarm is now Olpha! With our new name and brand, we are taking a bold step forward in our journey to transform from a regional player intoâ€¦",
        "meta_lang": "en",
        "meta_favicon": "https://static.licdn.com/aero-v1/sc/h/al2o9zrvru7aqj8e1x2rzsrca",
        "meta_site_name": "",
        "canonical_link": "https://www.linkedin.com/posts/olphaglobal_olpha-withinreach-activity-7209182164259622912-yJ5x",
        "text": "ğ’ğ­ğ«ğ¢ğğğ¬ ğğ¡ğšğ«ğ¦ğš ğ ğğ­ğ¬ ğ”ğ’ğ…ğƒğ€ ğ§ğ¨ğ ğŸğ¨ğ« ğğ«ğğ ğšğ›ğšğ¥ğ¢ğ§ ğ‚ğšğ©ğ¬ğ®ğ¥ğ ğŸ“Œ Strides pharma received permission from the United States Food and Drug Administration (USFDA) to sell a generic medicine for nerve pain. ğŸ“ŒStrides Pharma Global Pte Limited, a subsidiary of the business, has acquired approval from the US drug agency for Pregabalin capsules in various strengths (25 mg, 50 mg, 75 mg, 150 mg, 100 mg, 200 mg, 225 mg, and 300 mg). ğŸ“ŒThe product is bioequivalent and therapeutically equivalent to Upjohn US's Lyrica pills, which are a Reference Listed Drug. The capsule is used to treat fibromyalgia. #stridespharma #usfda #anda #pregabalin\n\nRicky Lakhani, Daljit Cheema and Corina Feraru were excellent companions at #COGEurope and proved how people make the difference, and why you should be talking to us about how the #Pharmaseal #Medrio partnership can benefit your projects. #medrio #pharmaseal #eclinical #cdms\n\nğŸš¨ ğ—¡ğ—²ğ˜„ ğ——ğ—²ğ˜ƒğ—²ğ—¹ğ—¼ğ—½ğ—ºğ—²ğ—»ğ˜ğ˜€ ğ—¶ğ—» ğ˜ğ—µğ—² ğ—£ğ—µğ—®ğ—¿ğ—ºğ—®ğ—°ğ—²ğ˜‚ğ˜ğ—¶ğ—°ğ—®ğ—¹ ğ—Ÿğ—®ğ—»ğ—±ğ˜€ğ—°ğ—®ğ—½ğ—²! Laprophan, the leading Moroccan laboratory, has emerged as a key player in the potential takeover of Recipharm. Laprophan, under the leadership of Dr. Farid Bennis, has presented a second \"firm\" offer, initiating a thirty-day exclusivity period that has captured the industry's attention. The surprising acceptance of the exclusivity period, expiring on March 29, has sidelined Astrea Pharma's bid, making Laprophan the imminent choice for Recipharm's future. As the deadline approaches, the question is to know how Laprophan's vision aligns with the future of Recipharm in Monts. We look forward to witnessing the impact that this collaboration may bring to the pharmaceutical landscape! ğŸŒ #PharmaceuticalIndustry #pharma\n\nDuring the discussion on Panel I: 'Drug prices in focus: The biggest challenges of drug manufacturers in Bosnia and Herzegovina', we analyze and investigate the pharmaceutical sector and how it faces new challenges. On the panel, we talked with Dr. Aziz Å ukalo, director of the BiH Region/market support sector director, Bosnalijek BiH, Benjamin Sahovic, president of the Management Board, FARMAVITA, and SaÅ¡a UroÅ¡eviÄ‡, GM, HEMOFARM BiH. \"The supply chain and the global functioning of the health sector were disrupted - then by the pandemic, and now in the world, and this greatly affects the medicine market in the Adria region,\" Å ahoviÄ‡ said. #pharmacy #pandemia #bloombergadria #conference\n\nThis week's Pearce IP #BioBlast features the following: - Amgen appeals Alexion Pharmaceuticals, Inc.â€™s preliminary injunction order regarding off-label use of #eculizumab (SolirisÂ®) biosimilar BekemvÂ® in Germany - FDA publishes draft guidance for biosimilar supplement classifications - Fresenius Kabi & Formycon AG settle with Johnson & Johnson in US over #ustekinumab enabling sales from no later than 15 April 2025 - Biocon confirms Viatris North American transition will complete by end Q3 2023 - Economic Development Bank For Puerto Rico grants $3.85M to Biosimilar Sciences and OcyonBio - UPC appoints 21 additional judges - Coherus BioSciencesâ€™ Q2 2023 financial results show quadrupling of #ranibizumab sales since last quarter Read more: https://lnkd.in/gxFknvtm #bioblast #biosimilars #boutiquelawfirm #australia #patentlaw #awardwinning #pearceip #patents #biopharma\n\nSTADA Eurasia aids to the open dialogue between the regulators of Kazakhstan and the international pharmaceutical industry at â€œGLOBAL PHARM 2023â€ held in Astana on Oct. 26th. During the annual round table with CEOs Arminas Macevicius , VP STADA Eurasia, voiced the need to be faster and more agile in taking decisions on streamlining market access of modern biosimilars to cover more patients and to improve the quality of their lives. #STADA #STADAEurasia\n\n#Imagine patients facing their illnesses without worrying if and when they will be experiencing pain, refraining them from living an active life. At Lavipharm, we imagined this and turned our vision into reality. We continue to invest in pain management. EFPIA - European Federation of Pharmaceutical Industries and Associations Î£Î¦Î•Î• / SFEE - Î£ÏÎ½Î´ÎµÏƒÎ¼Î¿Ï‚ Î¦Î±ÏÎ¼Î±ÎºÎµÏ…Ï„Î¹ÎºÏÎ½ Î•Ï€Î¹Ï‡ÎµÎ¹ÏÎ®ÏƒÎµÏ‰Î½ Î•Î»Î»Î¬Î´Î¿Ï‚ #WeWontRest #SFEE #EFPIA #Lavipharm #PainManagement\n\nThis is a story of success 2014 - Validation of the Olon #Daptomycin process 2017 - Launch of Olon Daptomycin in the US market, first API supplier to launch generic Daptomycin 2018 - Launch of Olon Daptomycin in Europe, first API supplier to launch generic Daptomycin 2024 - Olon makes investments towards significant expansion, reaching double its production capacity We celebrate 10 years of #Olon Daptomycin, announcing doubled production capacity #pharmasupplychain #pharma"
    }
}